CPRX · As filed with the SEC
Catalyst Pharmaceuticals income statement, by quarter
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Total revenues | 149,390,000 | — | 148,392,000 | 146,563,000 |
| License and other revenue | 47,000 | — | 27,000 | 23,000 |
| Product revenue, net | 149,343,000 | — | 148,365,000 | 146,540,000 |
| Operating costs and expenses: | ||||
| Cost of sales | 14,475,000 | — | 22,654,000 | 20,614,000 |
| Research and development | 2,661,000 | — | 2,657,000 | 4,358,000 |
| Selling, general and administrative | 49,319,000 | — | 47,470,000 | 45,949,000 |
| Amortization of intangible assets | 9,703,000 | — | 9,344,000 | 9,344,000 |
| Total operating costs and expenses | 76,158,000 | — | 82,125,000 | 80,265,000 |
| Operating income | 73,232,000 | — | 66,267,000 | 66,298,000 |
| Other income, net | 10,997,000 | — | 4,768,000 | 2,995,000 |
| Net income before income taxes | 84,229,000 | — | 71,035,000 | 69,293,000 |
| Income tax provision | 20,495,000 | — | 18,252,000 | 17,185,000 |
| Net income | 63,734,000 | — | 52,783,000 | 52,108,000 |
| Net income per share: | ||||
| Basic | 0.52 | — | 0.43 | 0.43 |
| Diluted | 0.5 | — | 0.42 | 0.41 |
| Weighted average shares outstanding: | ||||
| Basic | 122,254,171 | — | 122,600,730 | 122,163,212 |
| Diluted | 126,903,391 | — | 127,090,194 | 127,543,284 |
| Other comprehensive income (Note 4): | ||||
| Unrealized gain (loss) on available-for-sale securities, net of tax of ($3) and $25, respectively | 8,000 | — | (31,000) | 48,000 |
| Comprehensive income | 63,742,000 | — | 52,752,000 | 52,156,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.